FUJIFILM VisualSonics Launches the Vevo F2 LAZR-X20 Photoacoustic Imaging Platform for Preclinical Ultrasound
Article content
The world's first ultra-high to low frequency ultrasound system is designed to enhance research efforts across multiple applications, including oncology, cardiovascular, neurobiology and molecular biology
Article content
TORONTO — FUJIFILM VisualSonics Inc., a world leader in ultra-high frequency ultrasound and photoacoustic imaging systems, today announced the availability of the multi-modal Vevo F2 LAZR-X20 Photoacoustic Imaging Platform. The system features high-powered, intelligent laser technology for advanced tissue characterization with high anatomical accuracy for preclinical animal models.
Article content
'For more than two decades, FUJIFILM VisualSonics has been delivering ultra-high frequency ultrasound and photoacoustic imaging solutions to the scientific research community,' said Greg Nesbitt, vice president, global high frequency, FUJIFILM VisualSonics Inc. 'As a leader in the space, we saw an opportunity to expand the scope of questions that can be answered using photoacoustics. The Vevo LAZR-X20 underscores our commitment to constantly innovating and bringing more applications and capabilities to a broader set of research domains.'
The advanced laser technology in the Vevo F2 LAZR-X20 provides enhanced imaging depth and high-resolution in real time, allowing researchers to visualize and measure various tissue types and contrast agents. Leveraging a unique wavelength range of 660-1320 nm, the system unlocks advanced tissue characterization capabilities that were beyond reach with our previous-generation technologies. Tissue chromophores like lipids and collagen, which exhibit unique absorption profiles within this range, can be detected non-invasively. This enables researchers to visualize tumor microenvironments and opens the potential for quantifying therapeutic efficiency. This paves the way for possible deeper insights and more impactful discoveries.
Article content
'This cutting-edge product represents a significant advancement in our portfolio, seamlessly integrating photoacoustics with ultrasound imaging into a single platform,' said Andrew Needles, director, product innovation, FUJIFILM VisualSonics Inc. 'The new system provides excellent image quality and an expanded spectral range, providing researchers with comprehensive data for their imaging studies. We believe this breakthrough technology will not only enhance current research capabilities but also has the potential to unlock new applications, particularly in the fields of oncology and neurobiology.'
Article content
Learn more about the multi-modal Vevo F2 LAZR-X20 here. About Fujifilm FUJIFILM VisualSonics, Inc., is a global leader in real time, in vivo, ultra-high frequency ultrasound and photoacoustic imaging systems. With headquarters in Toronto, Canada and offices around the world, FUJIFILM VisualSonics is represented globally across an integrated sales network. FUJIFILM VisualSonics is recognized worldwide for providing cutting edge imaging technologies for the advancement of preclinical research, particularly in cardiovascular, oncology, neurobiology and developmental biology areas. With the expansion of the product portfolio to include a new preclinical product, FUJIFILM VisualSonics now broadens their range of imaging technologies across the preclinical market. FUJIFILM VisualSonics is a subsidiary of FUJIFILM Sonosite, Inc. and a part of FUJIFILM Holdings Corporation. For more information, please go to: www.visualsonics.com.
Article content
FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of 'giving our world more smiles,' we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: https://holdings.fujifilm.com/en.
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contact
Article content
Article content
Marissa Confredo
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
23 minutes ago
- CTV News
Manitoba has highest rate of stimulant toxicity deaths in Canada: data
Manitoba has the highest rate of stimulant-related deaths in all of Canada, according to new data. On Thursday, the Government of Canada released information regarding toxic drug poisonings in the country, showing that Canada has seen a climb in deaths from 2016 to 2024. Last year, Manitoba had the highest rate of stimulant drug-related deaths in the country, coming in at 30 deaths per 100,000 people. The numbers show that this amounted to 448 deaths in 2024, which is up from 412 deaths in 2023 and 317 deaths in 2022. When it comes to opioid toxicity deaths, Manitoba's 2024 crude rate was 24.8 per 100,000 people. This is the third highest rate in the country, with only British Columbia and the Yukon seeing higher rates. In terms of the numbers, 371 people died from opioid-related deaths in Manitoba last year. Though this number is down slightly from 382 deaths in 2023, it's still up substantially from when the Public Health Agency of Canada first began its tracking. When national surveillance started in 2016, there were 88 opioid toxicity deaths in the province, followed by 106 in 2017. The province saw a major jump in 2020 when it went up to 233 deaths, and the numbers only continued to climb from there. How does Manitoba compare? Manitoba falls somewhat in line with what is being seen across the rest of the country. In 2024, there were 7,146 opioid toxicity deaths across Canada and 3,931 stimulant-related deaths. Both numbers are down from the year prior, however, the data shows the country has seen a distinct rise in both opioid and stimulant-related deaths since 2020. In a statement, the provincial and territorial chief coroners, medical officers and medical examiners said Canada's overdose crisis is one of the biggest public health issues Canada has ever faced. The statement noted that though there was a drop in deaths in 2024, an average of 20 people died every day from opioid toxicity in Canada last year. 'All aspects of our strategies to respond to the drug toxicity crisis should be population and person-centered,' it said. 'This includes working together across prevention, treatment, harm reduction, and enforcement to provide solutions. The drug toxicity crisis is complex, and continued coordinated efforts between multi-sectoral partners are key to save lives and improve population health.' The full set of data can be found online.
Globe and Mail
40 minutes ago
- Globe and Mail
Why Duolingo Stock Plummeted This Week
Shares of the world's largest education app, Duolingo (NASDAQ: DUOL), were down 14% this week as of 2:30 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence. The main reason for this decline came from a Jefferies analyst highlighting that Duolingo's daily active user (DAU) growth slowed to 37% in June. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Analysts expected 44% growth in DAUs for the company's second quarter, but the data shows it'll be closer to 39%, prompting the adverse reaction from the market. Duolingo learns about decelerating DAU growth While 30 days' worth of disappointing DAU data isn't bad in and of itself, it extends a worrying trend. Over the last five months, the company's DAU growth declined from 56% in February to 53% in March, 41% in April, 40% in May, and finally 37% in June. This deceleration is far from a death knell for Duolingo's stock. But the market may be justified in lowering the company's valuation until it sees improving data. Even after this drop, the company trades at 106 times free cash flow, including stock-based compensation. However, following this decline, I may find myself buying more Duolingo shares soon, thanks to its promising growth optionality. Far from just a language learning app, Duolingo has multiple potential growth outlets, like: Adding to its courses, as it has already done with ABCs for children, math, music, and now chess. Building upon its standardized test offerings, such as its Duolingo English Test (roughly 10% of sales). Growing the advertising revenue from its non-subscriber tier (around 6% of sales). Incorporating artificial intelligence (AI) into its offerings, such as its video chat with Lily. Though its days of 50% hypergrowth may be in the past, Duolingo's longer-term growth story is still in its early chapters. Should you invest $1,000 in Duolingo right now? Before you buy stock in Duolingo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Duolingo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,731!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $945,846!* Now, it's worth noting Stock Advisor 's total average return is818% — a market-crushing outperformance compared to175%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
CBC
an hour ago
- CBC
'She's my hero': Young girl saves grandmother from stroke twice
It was like any other day on the farm, but within minutes, the ordinary turned life-changing. Meaka Star's quick recognition of a stroke may have saved her grandmother Marleen Conacher's life. They're sharing their story this June, Stroke Awareness Month, to raise awareness of the signs of stroke and the importance of acting fast. "She saved my life, or saved me at least from a life of maybe a wheelchair or not being able to talk, with her fast actions. She saved me and she'll always be my hero," Marleen said. Marleen was spending time with her two granddaughters in July 2021. The plan was simple: dinner, a movie and a relaxing night. Meaka, who was 10 years old at the time, noticed something was off. Her grandmother's voice had disappeared and her face was drooping. Then she collapsed. "I called dad and told him what was happening. So he told me to call 911," Meaka said in an interview on CBC's Saskatoon Morning. Her quick thinking got Marleen to the hospital just in time. Then it happened again six days later. Marleen, who was recovering from the last stroke, couldn't open a pill bottle. Meaka spotted the signs immediately. "I knew exactly what was happening again. So I called Dad. He told me to do the same thing, call 911. So I did. And then my Auntie Lori came and took Mama to the hospital," she said "They were really proud of me and really surprised that a 10-year-old did that." Meaka received a Hero Award at school. Marleen said her granddaughter is her hero. The FAST method for recognizing a stroke FAST (face, arms, speech, time) is an acronym for steps to take to assess whether someone is having a stroke. Face: Is their face drooping? Arms: Can they lift both of their arms? Speech: It it slurred or gone? Time: It's of the essence. If you think they could be having a stroke, call 911 right away. Another close call Carmi Levy, 46, is a stroke survivor. He's also a journalist and technology writer for CBC. He lives in London, Ont. He now uses his media voice to raise awareness about strokes. He said his main message during Stroke Awareness Month is to take symptoms seriously and seek care immediately. Levy was feeling fit and out for a bike ride in the summer of 2013 when a simple turning of his head tore an artery in his neck. Hours later while barbecuing for his family, he collapsed. "Thankfully my my wife had seen what happened. She saw me collapse, came out from inside the house," he said on CBC's Saskatchewan Weekend. "While I thought I had simply fainted, very quickly I realized I couldn't answer her questions. I couldn't speak." He also realized he couldn't get up and the right side of his body was paralyzed. His wife, a teacher, was trained in the FAST protocol as part of her school's first aid training. She noticed the signs and called 911 immediately. "When you have a stroke, it is essentially cutting off blood supply to your brain. Your brain cells die. The longer this takes, the more brain cells you lose and they don't grow back," he said. He said he was glad that he got the care he needed within the "window of opportunity." Levy said he's recovered, but his sense of balance is still a bit off sometimes as he leans against walls. "When I'm on the bike, I don't feel it at all. And the faster I go, the better it feels," he said. "I will always happily head to the same area where this happened, almost as a way of telling the universe, not my time yet."
